Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors

被引:41
|
作者
Yao, Zhangyu [1 ]
Wei, Xueying [1 ]
Wu, Xiaoming [1 ]
Katz, Jonathan L. [2 ]
Kopajtic, Theresa [2 ]
Greig, Nigel H. [3 ]
Sun, Hongbin [1 ]
机构
[1] China Pharmaceut Univ, Coll Pharm, Ctr Drug Discovery, Nanjing 210009, Peoples R China
[2] Natl Inst Drug Abuse, Psychobiol Sect, Intramural Res Program, NIH, Baltimore, MD 21224 USA
[3] NIA, Drug Design & Dev Sect, Lab Neurosci, Intramural Res Program,NIH, Baltimore, MD 21224 USA
关键词
Tetrabenazine enantiomers; Dihydrotetrabenazine stereoisomers; Resolution; Huntington's chorea; VMAT2; Hyperkinetic disorders; MONOAMINE TRANSPORTER; MOVEMENT-DISORDERS; METABOLITE; EPOXIDES; EMETINE; BINDING; DRUGS;
D O I
10.1016/j.ejmech.2011.02.046
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Tetrabenazine (TBZ) ((+/-)-1) and dihydrotetrabenazines (DHTBZ) are potent inhibitors of VMAT2. Herein, a practical chemical resolution of (+/-)-1 and stereoselective synthesis of all eight DHTBZ stereoisomers are described. The result of VMAT2 binding assay revealed that (+)-1 (K-i = 4.47 nM) was 8000-fold more potent than ()-1 (K-i = 36,400 nM). Among all eight DHTBZ stereoisomers, (2R,3R,11bR)-DHTBZ ((+)-2: K-i= 3.96 nM) showed the greatest affinity for VMAT2. The (3R,11bR)-configuration appeared to play a key role for VMAT2 binding. In summary, (+)-1, (+)-2, and their derivatives warrant further studies in order to develop more potent and safer drugs for the treatment of chorea associated with Huntington's disease and other hyperkinetic disorders. (C) 2011 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:1841 / 1848
页数:8
相关论文
共 50 条
  • [31] Utility of VMAT2 inhibitors in management of stereotypy in children: a series of six patients
    Hull, M.
    Parnes, M.
    MOVEMENT DISORDERS, 2020, 35 : S523 - S523
  • [32] Pyrrolidine analogs of GZ-793A: Synthesis and evaluation as inhibitors of the vesicular monoamine transporter-2 (VMAT2)
    Penthala, Narsimha Reddy
    Ponugoti, Purushothama Rao
    Nickell, Justin R.
    Deaciuc, Agripina G.
    Dwoskin, Linda P.
    Crooks, Peter A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (11) : 3342 - 3345
  • [33] 9-Cyclopropylmethoxy-dihydrotetrabenazine and its stereoisomers as vesicular monoamine transporter-2 inhibitors
    Wang, Wenyan
    Lin, Shilan
    Du, Guangying
    Bai, Xinfa
    Lu, Jing
    Ye, Liang
    Wang, Hongbo
    Zhang, Rui
    Tian, Jingwei
    FUTURE MEDICINAL CHEMISTRY, 2022, 14 (13) : 991 - 1003
  • [34] FEASIBILITY OF A COMPARATIVE META-ANALYSIS OF VMAT2 INHIBITORS FOR THE TREATMENT OF TARDIVE DYSKINESIA
    Caroff, S. M.
    Aggarwal, S.
    Yonan, C.
    VALUE IN HEALTH, 2017, 20 (05) : A189 - A189
  • [35] Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review
    Golsorkhi, Mohadese
    Koch, Jessa
    Pedouim, Farzin
    Frei, Karen
    Bondariyan, Niloofar
    Dashtipour, Khashayar
    TREMOR AND OTHER HYPERKINETIC MOVEMENTS, 2024, 14 : 1 - 12
  • [36] Real-World Use and Impact of VMAT2 Inhibitors in Patients with Tardive Dyskinesia
    Lundt, L.
    Franey, E.
    Yonan, C.
    MOVEMENT DISORDERS, 2020, 35 : S40 - S40
  • [37] Mutagenesis and derivatization of human vesicle monoamine transporter 2 (VMAT2) cysteines identifies transporter domains involved in tetrabenazine binding and substrate transport
    Thiriot, DS
    Ruoho, AE
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (29) : 27304 - 27315
  • [38] Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective
    Citrome, Leslie
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2018, 18 (04) : 323 - 332
  • [39] Synthesis and biological evaluation of all eight stereoisomers of DPP-IV inhibitor saxagliptin
    Dong, Jizhe
    Gong, Yanchun
    Liu, Jun
    Chen, Xiangfeng
    Wen, Xiaoan
    Sun, Hongbin
    BIOORGANIC & MEDICINAL CHEMISTRY, 2014, 22 (04) : 1383 - 1393
  • [40] Inhibitors of vesicular monoamine transporter type 2 (VMAT2) and the risk of anxiety and depression: meta-analysis
    Szejko, N.
    Cuenod, M.
    Macul Ferreira de Barros, P.
    Artukoglu, B.
    Flores, J.
    Nasir, M.
    Bloch, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 625 - 625